FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Market Closed - Deutsche Boerse AG 01:11:54 29/06/2024 am IST | ||
| 0.1 EUR | +11.11% |
|
| 1 month | -28.57% | ||
| 3 months | -41.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 0.1 | +11.11% |
| 27/24/27 | 0.09 | 0.00% |
| 26/24/26 | 0.09 | +2.27% |
| 25/24/25 | 0.088 | -12.00% |
| 24/24/24 | 0.1 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 29, 2024 at 01:11 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SQ67XP |
| ISIN | DE000SQ67XP2 |
| Date issued | 11/01/2023 |
| Strike | 956.4 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.15 € |
|---|---|
| Lowest since issue | 0.086 € |
| Spread | 0.01 € |
| Spread % | 9.09% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- Certificat
